GRAL · GRAIL, Inc. · Webcasts, Transcripts & Audio
$115.89
-5.46 (-4.50%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$5.21B
Shares
44.96M
Volume · Nov 13
361.16K
Avg daily vol (3M)
1.05M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
GRAIL, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for GRAIL, Inc. (GRAL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-10
GRAIL, Inc. (GRAL) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-04
GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript
Positive tone
FDA regulatory pathway
Payer and CMS reimbursement
Clinical evidence and publications
Revenue
$37.53M
▲ 3.7% YoY Diluted EPS
$-2.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
GRAIL, Inc. (GRAL) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
GRAIL, Inc. (GRAL) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript
Confident tone
Regulatory path (FDA approval, adcom, Medicare)
Samsung partnership and international expansion
Payer and employer coverage partnerships
Revenue
$44.69M
▲ 25.7% YoY Diluted EPS
$-2.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
GRAIL, Inc. (GRAL) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
GRAIL, Inc. (GRAL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript
Positive tone
FDA PMA review and approval timeline
NHS-Galleri and PATHFINDER 2 clinical data / ASCO
2026 guidance and conservatism
Revenue
$40.78M
▲ 28.1% YoY Diluted EPS
$-2.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-19
GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript
Positive tone
NHS-Galleri trial results
Commercial performance of Galleri
FDA PMA submission
Revenue
$43.60M*
▲ 14% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
GRAIL, Inc. (GRAL) January 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-10-20
GRAIL, Inc. (GRAL) Q3 2025 Earnings Call Transcript
Confident tone
Commercial volume and revenue growth
Clinical evidence - SIMPLIFY
Clinical evidence - PATHFINDER II
Revenue
$36.19M
▲ 26.3% YoY Diluted EPS
$-2.46
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
Confident tone
Galleri commercial volume growth
PATHFINDER 2 clinical study results
International expansion and tech transfer
Revenue
$35.54M
▲ 11.2% YoY Diluted EPS
$-3.18
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
Positive tone
NHS-Galleri Trial Results
NHS Commercialization Partnership
Test Performance and Real World Evidence
Revenue
$31.84M
▲ 19.1% YoY Diluted EPS
$-3.10
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
Positive tone
Galleri commercial momentum and test volume
Quest and TRICARE distribution/coverage expansion
Cash burn reduction and financial runway
Revenue
$38.25M*
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
GRAIL, Inc. (GRAL) Q3 2024 Earnings Call Transcript
Positive tone
Galleri test demand and commercial performance
FDA approval pathway and registrational studies
Reimbursement strategy and legislation
Revenue
$28.65M
▲ 38.3% YoY Diluted EPS
$-3.94
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
GRAIL, Inc. (GRAL) Q2 2024 Earnings Call Transcript
Positive tone
Galleri commercial performance and demand
FDA PMA submission and registrational studies
Corporate restructuring and cost reduction
Revenue
$31.97M
▲ 42.6% YoY Diluted EPS
$-51.06
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–16 of 16 webcasts
Key facts
CIK
1699031
CUSIP
384747101
13F (30d)
355 filings
321 filers
Visit website
Investor relations